Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$41.18 USD

41.18
3,160,813

+0.86 (2.13%)

Updated Aug 13, 2024 04:00 PM ET

After-Market: $41.19 +0.01 (0.02%) 7:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Novartis to Market Rizmoic Through Sandoz, Spins Off Alcon

Novartis' (NVS) Sandoz signs an agreement with Japanese company, Shionogi, to commercialize constipation drug in key European markets.

AstraZeneca/Merck's Lynparza Wins EU Nod for Breast Cancer

AstraZeneca (AZN) and Merck gain an EU approval for Lynparza as a monotherapy for treating HER2-negative locally-advanced/metastatic breast cancer.

Emergent's (EBS) Strong Vaccine Portfolio to Fuel Growth

Emergent's (EBS) vaccine portfolio looks promising. The company's recent acquisitions also bode well for growth.

Glaxo's Dovato Gets FDA Nod for Treatment-Naive HIV Patients

Glaxo's (GSK) ViiV Healthcare gets FDA approval for a single-tablet two-drug regimen (2DR), Dovato for treatment naive HIV- 1 adults.

Gilead Files sNDA for Label Expansion of HIV Therapy Descovy

Gilead (GILD) submits sNDA to the FDA for label expansion of Descovy as PrEP to reduce the risk of sexually acquired HIV-1 infection.

Sanghamitra Saha headshot

Health Day Checkup of Medical ETFs: 5 Top Picks

M&A activity, approval of novel drugs and earnings growth in Q1 put healthcare ETFs in a decent spot.

Novartis Resubmits BLA to FDA for Biosimilar of Neulasta

Novartis' (NVS) generic arm Sandoz resubmits its BLA for the proposed biosimilar of Neulasta.

Clovis Posts Data on Rubraca Study for Pancreatic Cancer

Clovis (CLVS) presents interim data from the phase II study on Rubraca for the first-line maintenance treatment of patients with advanced pancreatic cancer.

Novartis Gets Approval for Psoriasis Drug Cosentyx in China

Novartis' (NVS) psoriasis drug gets approval in China. The company also signs an agreement to expand its biologics therapy manufacturing capability.

Merck's Keytruda Gets Nod for First-Line Lung Cancer in China

Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting in China.

Kinjel Shah headshot

3 Big Pharma Stocks to Add to Your Portfolio This April

The large-cap pharma industry is on a strong footing in 2019. Here are three stocks from the space that investors may consider betting on.

Mark Vickery headshot

Top Analyst Reports for Chevron, IBM & Medtronic

Today's Research Daily features new research reports on 16 major stocks, including Chevron (CVX), IBM (IBM) and Medtronic (MDT).

Axsome's Depression Drug Gets Breakthrough Therapy Status

Axsome (AXSM) announces that the FDA has granted Breakthrough Therapy designation to AXS-05 for the treatment of major depressive disorder (MDD).

Swarup Gupta headshot

5 Cancer-Fighting Stocks to Boost Portfolio Gains

It would pay to invest in these companies which offer current franchises or prospective treatments for the most dreaded of diseases.

Emergent Begins Phase III Study on Anthrax Vaccine AV7909

Emergent (EBS) kicks off a late-stage study on its investigational anthrax vaccine AV7909.

Glaxo Presents Encouraging Data on Endometrial Cancer Drug

Glaxo (GSK) presents encouraging data from phase I/II study on endometrial cancer drug, dostarlimab.

Novartis' (NVS) Alcon Acquired PowerVision for $285 Million

Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.

GlaxoSmithKline (GSK) Stock Sinks As Market Gains: What You Should Know

GlaxoSmithKline (GSK) closed at $40.03 in the latest trading session, marking a -0.12% move from the prior day.

Should Value Investors Pick GlaxoSmithKline (GSK) Stock Now?

Let's see if GlaxoSmithKline (GSK) stock is a good choice for value-oriented investors right now from multiple angles.

Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy

Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.

Mark Vickery headshot

Top Research Reports for Microsoft, Mastercard & General Electric

Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Mastercard (MA) and General Electric (GE).

Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy

Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.

Roche's (RHHBY) sNDA for Flu Candidate Accepted by the FDA

The FDA accepts Roche's (RHHBY) sNDA for Xofluza to treat influenza in people at high risk of complications.

Merck Gets CHMP Nod for Six-Week Dosing Option of Keytruda

Merck (MRK) gets CHMP recommendation for a six-week dosing schedule of Keytruda across all current monotherapy indications.

Mallinckrodt (MNK) Rallies as Earnings Beat Estimates in Q4

Mallinckrodt (MNK) tops earnings and sales estimates in the fourth quarter leading to a gain in share price.